Abstract:Objective To develop preclinical orthotopic model in nude mice for sensitive prostate cancer cell tracking during tumor progression using bioluminescent technique.Methods The human prostate cancer cell line PC3 cells were transduced with green fluorescent protein (GFP) -luciferase fusion gene by a lentivirus vector which can express high activity of luciferase and GFP.Stably transduced GFP-LucPC3 monoclonal cells were got with Blasticidin selection.Labeled or normal tumor cells ( 5 × 106 ) were implanted into the flanks of 6 animals to build up an intradermal xenograft prostate cancer model,which provided prostate cancer graft to build the orthotopic prostate tumor model,and to confirm the tumorigenesis ablitiy of GFP-Luc-PC3.Tumor tissue from the either PC3 or GFP-Luc-PC3 line tumors was harvested and cut into pieces of about 2 mm3.These were grafted into the anterior prostates of 24 male animals which were randomly divided into two groups.The tumor growth was monitored by both WIS 200 and ex vivo tumor weight analysis 2,4,6 and 8 weeks after tumor tissue grafting.The bioluminescent signal values as well as tumor weight was measured,and their relationship was analyzed accordingly.Results A GFP-LucPC3 cell line was established which had the same growth pattern as well as tumorigenesis ability as normal PC3 cells.There was a positive linear correlation between bioluminescent signal and cell number with the coefficient factor r =0.997.In orthotopic prostate cancer model,all 12 mice in GFP-Luc-PC3 group developed prostate tumor,from which the bioluminescent signal could be recorded.In normal PC3 group,there was no significant bioluminescent signal.The bioluminescent values (photons/second) in vivo were (69.13298±2.07900) E+05,(82.66208±1.231 00) E+05,(91.94257±2.321 00) E+05 and ( 130.643 40 ± 3.247 00) E + 05 respectively 2,4,6 and 8 weeks after tumor tissue implantation.The tumor weight ex vivo was ( 9.67 ± 1.07 ),( 12.47 ± 2.12),( 16.45 ± 2.57 ),and ( 21.43 ± 4.56 ) g accordingly.There was a positive linear correlation between in vivo bioluminescent values and ex vivo tumor weight with coefficient being 0.973,P ＜0.05.Conclusion Our findings demonstrate the ability of the luciferase labeled tumor cells combinated within vivo bioluminesence imaging system is an excellent experimental animal model in tracking the location,magnitude and persistence of luciferase expression cells in human prostate cancer mouse models,which may be usful in non-invasively monitoring on progression of prostate cancer in vivo,even after the metastasis of the tumor.

[Bioluminescent Imaging Monitoring of a Anti-Angiogenesis Therapeutic Gene Vasostatin in Tumor Cell PC3].

Development Of A Percutaneous Optical Imaging System For Tracking Vasclar Gene Expression: An Ultrasound-Guided Ex Vivo Feasibility Study

Magnetic Resonance Imaging Permits In Vivo Monitoring Of Catheter-Based Vascular Gene Delivery

Percutaneous Optical Imaging System to Track Reporter Gene Expression from Vasculatures in Vivo

Molecular Imaging of Tumor Angiogenesis and Therapeutic Effects with Dual Bioluminescence

Assessment of therapeutic efficacy of liposomal nanoparticles mediated gene delivery by molecular imaging for cancer therapy.

In vivo US monitoring of catheter-based vascular delivery of gene microspheres in pigs: feasibility.

Optical imaging of green fluorescent protein markers for tracking vascular gene expression: a feasibility study in human tissue-like phantoms

Development of A Percutaneous Optical Imaging System for Tracking Vascular Gene Expression: A Feasibility Study Using Human Tissue Like Phantoms

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Noninvasive Imaging of Enhanced Prostate-Specific Gene Expression Using a Two-Step Transcriptional Amplification-Based Lentivirus Vector.

Digital optical imaging of green fluorescent proteins for tracking vascular gene expression: feasibility study in rabbit and human cell models.

Non-invasive Bioluminescence Imaging of Myoblast-Mediated Hypoxia-Inducible Factor-1 Alpha Gene Transfer

Non-invasive Imaging of GFP-luciferase Labeled Orthotopic Prostate Cancer Model in Nude Mice Using Bioluminescence System

Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector

A Gene Therapy for Cancer Based on the Angiogenesis Inhibitor, Vasostatin.

Molecular In Vivo Imaging Using A Noninvasive Cardiac-Specific Mlc-2v Promoter Driven Dual-Gene Recombinant Lentivirus Monitoring System

Application of MRI and Bioluminescence Dual Reporter Gene Imaging for in Vivo Monitoring of Tumor Growth

Combined Bioluminescence and Fluorescence Imaging Visualizing Orthotopic Lung Adenocarcinoma Xenograft in Vivo.

In Vivo Real-Time Monitoring of the Development of Hypoxia and Angiogenesis in Cervical Cancer